Vertex Pharmaceuticals (VRTX) announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use adopted an opinion ...
The companies were two years into a four-year, $400 million agreement aimed at developing and marketing gene therapies ...
Verve offered few details on the early end of a collaboration the companies inked in 2022, saying only that Vertex cited “changing priorities.” ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback